Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination

Human Gene Therapy

Volumn 8, Issue 11, 1997, Pages 1355-1363

  Wan, Yonghong ^a   Bramson, Jonathan ^a   Carter, Ronald ^a   Graham, Frank ^a   Gauldie, Jack ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; TUMOR ANTIGEN; TUMOR VACCINE; VIRUS MIDDLE T ANTIGEN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW; BREAST CARCINOMA; CANCER IMMUNIZATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENETIC TRANSDUCTION; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LYMPHATIC SYSTEM; MOUSE; NONHUMAN; POLYOMA VIRUS; SPLEEN; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSGENE; TUMOR IMMUNITY;

ADENOVIRIDAE; ANIMALIA; MURINAE; POLYOMAVIRUS;

EID: 0030820002     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1997.8.11-1355     Document Type: Article

References (46)

1. ADDISON, C.L., BRACIAK, T., RALSTON, R., MULLER, W.J., GAULDIE, J., and GRAHAM, F.L. (1995). Intra-tumoral injection of an adenovirus expressing interleukin-2 induces regression and immunity in a murine breast cancer model. Proc. Natl. Acad. Sci. USA 92, 8522-8526.
2. AICHELE, P., BRDUSCHA-RIEM, K., ZINKERNAGEL, R.M., HENGARTNER, H., and PIRCHER, H. (1995). T cell priming versus T cell tolerance induced by synthetic peptides. J. Exp. Med. 182, 261-266.
3. ANDREWS, D.W., GUPTA, J., and ABISDRIS, G. (1993). Evidence that the middle T antigen of polyomavirus interacts with the membrane skeleton. Mol. Cell. Biol. 13, 4703-4713.
4. AUSTYN, J.M. (1996). New insights into the mobilization and phagocytic activity of dendritic cells. J. Exp. Med. 183, 1287-1292.
5. AUSTYN, J.M., KUPIEC-WEGLINSKI, J.W., HANKINS, D.F., and MORRIS, P.J. (1988). Migration patterns of dendritic cells in the mouse. Homing to T cell-dependent areas of spleen, and binding within marginal zone. J. Exp. Med. 167, 646-651.
6. BECKER, T.C., NOEL, R.J., COATS, W.S., GOMEX-FOIX, A.M., ALAM, T., GERARD, R.D., and NEWGARD, C.B. (1994). Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 43, 161-189.
7. BETT, A.J., PREVEC, L., and GRAHAM, F.L. (1993). Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol. 67, 5911-5921.
8. BETT, A.J., HADDARA, W., PREVEC, L., and GRAHAM, F.L. (1994). An efficient and flexible system for construction of adenovirus vectors with inserts or delection in early regions 1 and 3. Proc. Natl. Acad. Sci. USA 91, 8802-8806.
9. BOCZKOWSKI, D., NAIR, S.K., SNYDER, D., and GILBOA, E. (1996). Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465-472.
10. BOON, T., COULIE, P., MARCHAND, M., WEYNANTS, P., WOLFEL, T., and BRICHARD, V. (1994). Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. In Important Advances in Oncology. V.T. DeVita, S. Hellman, and S. Rosenberg, eds. (JB Lippincott Co., Philadelphia, PA) p. 53.
11. BRAMSON, J.L., GRAHAM, F.L., and GAULDIE, J. (1995). The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr. Opinion Biotechnol. 6, 590-595.
12. BROWNING, M.J., and BODMER, W.F. (1992). MHC antigens and cancer: Implications for T-cell surveillance. Curr. Opinion Immunol. 4, 613-618.
13. CELLUZZI, C.M., MAYORDOMO, J.I., STORKUS, W.J., LOTZE, M.T., and FALO, L.D. (1996). Peptide-pulsed dendritic cells induce antigen-specific, cytotoxic T lymphocyte-mediated protective tumor immunity. J. Exp. Med. 183, 283-287.
14. CHEN, L., ASHE, S., BRADY, W., HELLSTROM, I., HELLSTROM, K.E., LEDBETTER, J.A., McGOWAN, P., LINSLEY, P.S. (1992). Costimulation of antitumor immunity by the B7 counter-receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-1102.
15. CHEN, P.W., WANG, M., BRONTE, V., ZHAI, Y, ROSENBERG, S.A., and RESTIFO, N.P. (1996). Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol. 156, 225-231.
16. DAVIDSON, D., and HASSELL, J.A. (1987). Overproduction of polyomavirus middle T antigen in mammalian cells through the use of an adenovirus vector. J. Virol. 61, 1226-1239.
17. DOYLE, A., MARTIN, W.J., FUNA, K., GAZDAR, A., CARNEY, D., MARTIN, S.E., LINNOILA, I., CUTTITTA, F., MULSHINE, J., BUNN, P., and MINNA, J. (1985). Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J. Exp. Med. 161, 1135-1151.
18. EBERL, G., WIDMANN, C., and CORRADIN, G. (1996). The functional half-life of H-2Kd-restricted T cell epitopes on living cells. Eur. J. Immunol. 26, 1993-1999.
19. FISHER, K.J., JOOSS, K., ALSTON, J., YANG, Y., HAECKER, S.E., HIGH, K., PATHAK, R., RAPER, S.E., and WILSON, J.M. (1997). Recombinant adeno-associated virus for muscle directed gene therapy. Nature Med. 3, 306-312.
20. FLAMAND, V., SORNASSE, T., THIELEMANS, K., DEMANE, C., BAKKUS, M., BAZIN, H., THIELEMANS, F., LEO, O., URGAIN, J., and MOSER, M. (1994). Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24, 605-610.
21. GRABBE, S., BEISSERT, S., SCHWARZ, T., and GRANSTEIN, R.D. (1995). Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol. Today. 16, 117-121.
22. GRAHAM, F.L., and PREVEC, L. (1992). Adenovirus-based expression vectors and recombinant vaccines. In Vaccines: New Approaches to Immunological Problems. C.R.W. Ellis, ed. (Butterworth-Heinemann, Boston, MA) pp. 363-389.
23. GUY, C.T., CARDIFF, R.D., and MULLER, W.J. (1992). Induction of mammary tumors by expression of polyomarvirus middle T oncogene: a transgene mouse model for metastalic disease. Mol. Cell. Biol. 12, 954-961.
24. HITT, M., ADDISON, C., and GRAHAM, F.L. (1997). Human adenovirus vectors for gene transfer into mammalian cells. In Advances in Pharmacology - Gene Therapy. J. Thomas August, ed. (Academic Press, Orlando, FL) (in press).
25. HOUGHTON, A.N. (1994). Cancer antigens: Immune recognition of self and altered self. J. Exp. Med. 180, 1-4.
26. HUARD, J., LOCHMULLER, H., ACSADI, G., JANI, A., and KARPATI, G. (1995). The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 2, 107-115.
27. INABA, K., ROMANI, N., and STEINMAN, R.M. (1989). An antigen-independent contact mechanism as an early step in T cell-proliferative responses to dendritic cells. J. Exp. Med. 170, 527-542.
28. INABA, K., INABA, M., ROMANI, N., AYA, H., DEGUCHI, M., IKEHARA, S., MURAMATSU, S., and STEINMAN, R.M. (1992). Generation of large number of dendritic cells from mouse bone marrow cultures supplemented with GM-CSF. J. Exp. Med. 176, 1693-1702.
29. LARSEN, C.P., MORRIS, P.J., and AUSTYN, J.M. (1990). Migration of dendritic leukocytes from cardiac allografts into host spleens: A novel pathway for initiation of rejection. J. Exp. Med. 171, 307-314.
30. LASSAM, N., and JAY, G. (1989). Suppression of MHC class I RNA in highly oncogenic cells occurs at the level of tanscription initiation. J. Immunol. 143, 3792-3797.
31. LOCHMULLER, H., PETROF, B.J., PARI, G., LAROCHELLE, N., DODELET, V., WANG, Q., ALLEN, C., PRESCOTT, S., MASSIE, B., NALBANTOGLU, J., and KARPATI, G. (1996). Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. Gene Ther. 3, 706-716.
32. MAYORDOMO, J.I., ZORINA, T., STORKUS, W.J., CELLUZZI, C., FALO, L., KAST, W.M., ILDSTAD, S.T., DELEO, A.B., and LOTZE, M.T. (1995). Bone marrow-derived dendritic cells pulsed with tumor peptides elicit protective and therapeutic anti-tumor immunity. Nature Med. 1, 1297-1302.
33. MITTAL, S.K., McDERMOTT, M.R., JOHNON, D.C., PREVEC, L., and GRAHAM, F.L. (1993). Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter. Virus Res. 28, 67-90.
34. OSSEVOORT, M.A., FELTKAMP, M.C., VAN VEEN, K.J., MELIEF, C.J., and KAST, W.M. (1995). Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J. Immunother. 18, 86-94.
35. PARDOLL, D.M. (1994). Tumor antigens: A new look for the 1990s. Nature 369, 357-358.
36. PORGADOR, A., SNYDER, D., and GILBOA, E. (1996). Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156, 2918-2926.
37. + T-lymphocytes. Lab. Invest. 75, 67-76.
38. STEINMAN, R.M., WITMER-PARK, M., and INABA, K. (1993). Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv. Exp. Med. Biol. 329, 1-9.
39. TOLOZA, E.M., HUNT, K., SWISHER, S., McBRIDE, W., LAU, R., PANG, S., RHOADES, K., DRAKE, T., BELLDEGRUM, A., GLASPY, J., and ECONOMOU, J.S. (1996). In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther. 3, 11-17.
40. + T cells by B7-transfected melanoma cells. Science 259, 368-370.
41. XING, Z., BRACIAK, T., JORDANA, M., CROITORU, K., GRAHAM, F.L., and GAULDIE, J. (1994). Adenovirus-mediated cytokine gene transfer at tissue sites: overexpression of IL-6 induces lymphocytic hyperplasia in the lung. J. Immunol. 153, 4059-4069.
42. YANG, Y., ERTL, H.C., and WILSON, J.M. (1994). MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1, 433-442.
43. YANG, Y., LI, Q., ERTL, H.C., and WILSON, J.M. (1995). Cellular and humoral responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004-2015.
44. + CTLs in vivo. J. Immunol. 155, 2564-2570.
45. ZHAI, Y., YANG, J.C., KAWAKAMI, Y., SPIESS, P., WADSWORTH, S.C., CARDOZA, L.M., COUTURE, L.A., SMITH, A.E., and ROSENBERG, S.A. (1996). Antigen-specific tumor vaccines: Development and characterization of recombinant adenoviruses encoding MART1 or gp 100 for cancer therapy. J. Immunol. 156, 700-710.
46. ZITVOGEL, L., MAYORDOMO, J.I., TJANDRAWAN, T., DELEO, A.B., CLARKE, M.R., LOTZE, M.T., and STORKUS, W.J. (1996). Therapy of murine tumors with tumor peptide pulsed dendritic cells: dependence on T cells, B7 costimulation, and Th1-associated cytokines. J. Exp. Med. 183, 87-97.